IMDG -- Biopharmaceutical industry
The glycated hemoglobin detection is the golden standard of detecting diabetes that is confirmed by the world medical community.
IMDG -- Biopharmaceutical industry
The biotechnology industry is quietly developing in Dongguan. Currently, it has initially formed a industrial cluster in Song Shan Lake, as a core promotion area, which brings together more than 180 biotechnology related enterprises, including medical instruments, medicine, health products and other products enterprises. With the gradually settling in of East Sunshine Pharmaceutical, Guangdong Bomai, Guangdong Sequoia, and other domestic and foreign well-known biotechnology companies, a group of independent R&D products is also gradually introduced into the market, to fill the gaps of the domestic technology, at the same time, it increases the confidence of the market demand.
The biotechnology industry has been treated as the “one hundred thousand million magnitude”. Nowadays, “Song Shan Lake biotechnology” is well known, and for the next step, Dongguan will introduce special biotechnology policy, and establish industrial guiding funds to help enterprise to resolve funding, registration approval, and other essential problems, performing well in the role of “butler service”. Based on the plan, Dongguan will be continually introducing some high-quality biotechnology enterprises, such as large pharmaceutical enterprises, and the goal is that, the Song Shan Lake biotechnology industry value will reach 200 billion Yuan in 2025.
Uniten Biotechnology Co.,Ltd
Uniten specialized in diabetes diagnosis, it use the automatic system to open the market
Uniten only spend two years to establish and settle down in Song Shan Lake and has expanded throughout the whole country, it has gain wide recognition in the industry and the market. The developing pace of Uniten makes many biotechnology companies feels hopeless. Uniten’s amazing core product – Automatic glycosylated hemoglobin detection system, has broken the monopoly of foreign enterprises in the Chinese market, and it has fill the blank of domestic independent R&D of diabetes detection technology.
The chairman of Uniten – Mr. Lai, he majored in medicine, he was engaged in inspection work after he graduated from the medical college, and then he transfered to be a salesman to sell medical device products. The professional knowledge background and the sales experience, has made him to target the R&D area of diabetes detection. The glycated hemoglobin test can stably reflect the last 2 to 3 months average blood glucose level; currently it is the world's recognized golden standard for medical treatment of diabetes. “Diabetes detection technology abroad has patents, both their technology, and raw materials procurement, the whole chain is very secretary.” Mr. Lai said, the R&D process is really difficult, “although we know glycated hemoglobin concentration can be use for diagnose diabetes, but we still need to develop a new detection technology, and we need to constantly test and retest. The R&D process even will even influenced by the weather, temperature and other factors."
Eventually, Uniten took two years, invested more than 10 million Yuan, and developed the diabetes detection technology which belongs to China. According to the introduction by Mr. Lai, the glycated hemoglobin detection system is using the boronic affinity chromatography, which is the initiator in China; the technology has achieved the advance level in the world standard. “The most important thing is that, this independent R&D technology not only solves the problem of raw material, but also breaks the long-standing situation, which the diabetes detection is monopolized by foreign enterprises, and fills the gaps of the shortage of Chinese technology.”
In July 2014, Uniten was officially registered, allocated in the Song Shan Lake High-Tech Park Dongguan Taiwan Advanced Technology Developing District.
Uniten’s device installation capacity ranked No.1 in China, the price is also cheaper than foreign products.
With the introduction of the national "grading treatment" policy, the early screening, diagnosis, prevention and treatment of diabetes and other chronic diseases have been gradually sinking, as standardized management by the primary medical institutions. “Since the laboratory equipment is more expensive, and requires regular maintenance, a lot of primary medical institutions don’t have the ability to purchase the device for detecting glycated hemoglobin, which limits the role that the primary hospital should play. “ Mr. Lai said: “in this background, we independently developed a glycated hemoglobin detection system which will be able to solve the problem of the market, meanwhile, it is able to meet the basic needs of convenient and fast detection requirements of the primary clinical institutions.”
Generally speaking, from a project been approved, R&D, and then being introduced into the market, a biotechnology products at less requires 5 to 6 years to complete these processes. However, Uniten was just established less than 2 years ago, and its products have been successfully launched, and had garnered a great response. In 2015, Guangdong Uniten launched the semi-auto glycated hemoglobin test system that has been awarded the product registration certificate issued by Guangdong Food and Drug Administration. In March this year, the device has again received optimization and upgrading, the automatic glycated hemoglobin detection system has been introduced to the market, it not only gain the attention of the domestic medical equipment industry, but also has certain reputation in the Southeast Asian market. “This is an automatic device which can detect four samples simultaneously, and it can be operated by one button, the test result can come out in 7 seconds, it is very convenient and efficient.” The domestically produced detection device could significantly reduce the detection cost of diabetes, “the price will be at least 1/3 cheaper than the foreign products.”
“Last year, the installation capacity of our glycated hemoglobin testing device has ranked No. 1 in China, all prefecture level cities has 100% installed our device." Mr. Lai said, according to our plan, we will complete more than 60% of the county level installation next year, and gradually enter the market of higher level hospital. Furthermore, the R&D of diabetes detection will still keep going. The most common diabetes hazards are cardiovascular, cerebrovascular, renal, retinal disease and other complications. “In the future, we will introduce molecular screening projects, supporting the diagnosis of diabetic complications.”
This article is excerpts from Southern Metropolis Daily.
Link of the original article: http://www.oeeee.com/html/201607/26/406948.html